

Investing in Cardiovascular Disease

Millions of people worldwide suffer from heart and vascular disease. These conditions frequently result in heart attack, heart failure and stroke. While many therapies are currently available, none effectively treat or adequately prevent the underlying disease.

The aging population and increasing incidence of heart disease underscore the need for new technologies to address cardiovascular disease.

Research Corporation Technologies has targeted cardiovascular disease as an area of large unmet medical need and is actively looking for promising work with commercial potential. We are interested specifically in:

- Preclinical and early clinical candidate compounds to treat or prevent cardiomyopathies, hypertension, atherosclerosis, reperfusion-related conditions, and myocardial and cerebral infarction
- Preclinical and early clinical devices for treating and preventing cardiac, peripheral and cerebral vascular disease, cardiac valve disorders, cardiac conduction disorders, and conditions associated with heart failure

RCT has assets of more than \$300 million to advance technology development activities through flexible, long-term investment options. We focus our investments on opportunities that promise patented biomedical products with a clear competitive advantage.

If you are a start-up or early-stage company, RCT invests in companies whose technologies have the potential to become significant biomedical products through our RCT BioVentures program. Our initial financial commitment to our portfolio companies usually ranges from several hundred thousand dollars to several million dollars, and we reserve additional funds for the subsequent funding of successful companies. We can also invest management resources if needed.

If you have a new therapeutic, RCT can help it move from bench to bedside. We can provide money and management to advance a promising new drug into clinical trials through a variety of business arrangements, including licenses and development partnerships.

If your company or technology meets our criteria and needs further development and commercialization, we would like to hear from you. Please contact us to begin a confidential review of your opportunity.



5210 E. Williams Circle
Suite 240
Tucson, Arizona 85711-4410
Telephone: (520) 748-4400
Fax: (520) 748-0025
Web: www.rctech.com

Contact: Kurt Gehlsen, Ph.D., at (520) 748-4460 or kgehlsen@rctech.com